News Column

ENDOCYTE INC FILES (8-K) Disclosing Change in Directors or Principal Officers

June 19, 2014



ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF

DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS



On June 16, 2014, the Board of Directors of Endocyte, Inc. (the "Company") appointed Michael A. Sherman, currently the Company's Chief Financial Officer, to the newly-created position of Chief Operating Officer of the Company. Mr. Sherman will assume responsibility for additional operational functions at the Company, and he will continue to also serve as the Chief Financial Officer of the Company. The compensatory and other arrangements between Mr. Sherman and the Company have not changed.

Mr. Sherman, age 48, has served as the Company's Chief Financial Officer since October 2006. From December 1994 to October 2006, Mr. Sherman served in various executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006, of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College. There are no family relationships between Mr. Sherman and any director or other executive officer of the Company. There are no transactions between Mr. Sherman and the Company that would be required to be disclosed under Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters